JAGSNPHARM

Jagsonpal Pharmaceuticals Share Price

 

 

Invest in Jagsonpal Pharmaceuticals with 2.25X leverage

Invest with MTF
Jagsonpal Pharmaceuticals live price: ₹186.22. It opened at ₹185 vs previous close ₹186; intraday high/low: ₹187/₹184. The 50 & 200 DMA stand at ₹180.76/₹200.29.

Jagsonpal Pharmaceuticals Performance

  • Today's Low
  • ₹184
  • Today's High
  • ₹187
  • 52 Week Low
  • ₹155
  • 52 Week High
  • ₹302
  • Open Price₹185
  • Previous Close₹186
  • Volume58,776
  • 50 DMA₹180.76
  • 100 DMA₹188.92
  • 200 DMA₹200.29

Investment Returns

  • Over 1 Month + 10.4%
  • Over 3 Month -3.28%
  • Over 6 Month -16.26%
  • Over 1 Year -14.2%

Smart Investing Starts Here Start SIP with Jagsonpal Pharmaceuticals for Steady Growth!

Invest Now

Jagsonpal Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 30.5
  • PEG Ratio
  • -1.4
  • Market Cap Cr
  • 1,247
  • P/B Ratio
  • 4.7
  • Average True Range
  • 6.6
  • EPS
  • 6.36
  • Dividend Yield
  • 1.3
  • MACD Signal
  • 2.18
  • RSI
  • 58.51
  • MFI
  • 68.05

Jagsonpal Pharmaceuticals Financials

Jagsonpal Pharmaceuticals Technicals

EMA & SMA

Current Price
₹186.22
+ 0.56 (0.3%)
pointer
  • Bearish Moving Average 5
  • Bullish Moving Average 11
  • 20 Day
  • ₹181.02
  • 50 Day
  • ₹180.76
  • 100 Day
  • ₹188.92
  • 200 Day
  • ₹200.29

Resistance and Support

185.52 Pivot Speed
  • R3 189.94
  • R2 188.42
  • R1 187.04
  • S1 184.14
  • S2 182.62
  • S3 181.24

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Jagsonpal Pharmaceuticals manufactures and markets pharmaceutical formulations, focusing on therapeutic areas like gynecology, orthopedics, and cardiovascular health. It serves both domestic and international markets, providing high-quality medicines to improve healthcare outcomes.

Jagsonpal Pharmaceuticals has an operating revenue of Rs. 281.58 Cr. on a trailing 12-month basis. An annual revenue growth of 27% is outstanding, Pre-tax margin of 26% is great, ROE of 23% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and around 5% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 51 which is a POOR score indicating inconsistency in earnings, a RS Rating of 59 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 40 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Jagsonpal Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-03-12 Buy Back of Shares
2026-01-21 Quarterly Results
2025-11-03 Quarterly Results
2025-07-26 Quarterly Results
2025-05-06 Audited Results & Final Dividend
Date Purpose Remarks
2025-09-12 FINAL Rs.2.50 per share(125%)Final Dividend
2024-09-06 FINAL Rs.5.00 per share(100%)Final Dividend
2023-08-21 FINAL Rs.5.00 per share(100%)Dividend
2021-11-01 INTERIM Rs.4.00 per share(80%)Interim Dividend
View Jagsonpal Pharmaceuticals Dividend History Arrow
Date Purpose Remarks
2025-01-08 Split Rs.0.00 split from Rs. 5/- to Rs. 2/-.

Jagsonpal Pharmaceuticals F&O

Jagsonpal Pharmaceuticals Shareholding Pattern

67.39%
0%
2.12%
0%
21.2%
9.29%

Jagsonpal Pharmaceuticals FAQs

Jagsonpal Pharmaceuticals share price is ₹186 As on 02 April, 2026 | 17:23

The Market Cap of Jagsonpal Pharmaceuticals is ₹1247 Cr As on 02 April, 2026 | 17:23

The P/E ratio of Jagsonpal Pharmaceuticals is 30.5 As on 02 April, 2026 | 17:23

The PB ratio of Jagsonpal Pharmaceuticals is 4.7 As on 02 April, 2026 | 17:23

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23